A DOUBLE-BLIND, DOUBLE-DUMMY, ACTIVE-CONTROLLED, ORAL, MULTIPLE-DOSE, PARALLEL, RANDOMIZED STUDY TO EVALUATE EFFICACY AND SAFETY OF ENDOXIFEN IN BIPOLAR I DISORDER PATIENTS - NA
Latest Information Update: 18 Nov 2021
At a glance
- Drugs Endoxifen (Primary) ; Valproate semisodium
- Indications Bipolar I disorders
- Focus Registrational; Therapeutic Use
- Sponsors Intas Pharmaceuticals
- 16 Mar 2019 Primary endpoint has not been met. (Mean change in total YMRS score)
- 16 Mar 2019 Status changed from recruiting to completed according to results presented at the 120th Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics.
- 16 Mar 2019 Results presented at the 120th Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics